Erratum to: “The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients”

The published article¹ by mistake failed to list the author Liesbeth C. de Wreede, who as a statistician made essential contributions to the work by evaluating the age-dependent excess mortality in the patient population. She also helped to design the study, analyzed the data in comparison to the age-related mortality of a normal population and wrote/ corrected the manuscript.

Her name has been added to the list of authors and her affiliation is now correctly listed as: ⁴⁰Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands. Her name has also been added to the Contributions and the correct Contributions are therefore as follows: SM, LGa, LGr, MA, YA, LCdW, and DN designed the study. LK, LB, AD, NEM, PH, WS, AC, MI, SO, HT, SM, KK, YK, NH, BSK, CL, KWH, ASG, SKT, AME, AB, QNC, RA, MAB, MB, CAFO, ER, SG, FB, HM, AMcC, FRW, MK, JS, SS, DMcL, PH, AS, and HG enrolled patients. SM, LGa, LGr, DNe, NH, MA, YA, LCdW, and DN analyzed the data. SM, LGa, LGr, DNe, NH, MA, EV, YA, GS, LCdW, and DN wrote the manuscript. Furthermore the correct Disclosures are as follows: SM received research funding from Hayashikane Sangyo and lecture fees from Johnson & Johnson. AD’S reports clinical trial funding to institution from Abbvie, Alexion, Prothena, Janssen, Novartis, and Regeneron; discloses IRC, data monitoring committee, or steering committee role with Abbvie, BMS, Janssen, and Prothena; further discloses an advisory nboard role with Abbvie, BMS, Janssen, Prothena, and Pfizer. MI received research funding from AIR WATER Inc.. HT received honorarium from Janssen, Ono, Sanofi, and Bristol-Myers Squibb; and discloses consultancy fees from Adaptive Biotechnologies. KK discloses honoraria from Sanofi. JAS discloses consulting fees from Medac, Jazz, MSD, and Vertex. YA received lecture fee/honorarium from Otsuka Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Meiji Seika Pharma Co. Ltd., and Janssen Pharmaceutical K.K.; and discloses consultant fees from JCR Pharmaceuticals Co., Ltd. LG received consultancy fees from Janssen, Bristol-Myers Squibb, Sanofi, Pfizer, and GSK. All other authors including LCdW have no conflicts of interest to disclose.

Footnotes

• Received March 12, 2026
• Accepted March 12, 2026

Correspondence

^#DWN and LG contributed equally as senior authors

S. Mizuno shohei@aichi-med-u.ac.jp